← Back to Search

HEROIC Program for Caregivers of Heart Failure Patients (HEROIC Trial)

N/A

Waitlist Available

Led By Martha Abshire Saylor, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 12 and 24 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial will provide a program for caregivers of advanced heart failure patients to help improve their quality of life, sense of burden, and health.

Who is the study for?

This trial is for caregivers aged 50 or older of advanced heart failure patients who were hospitalized within the last 6 months. Caregivers must be willing to work on health goals, live with or visit the patient frequently, and be a spouse/partner or child of the patient. Those with terminal illnesses or cognitive impairment are excluded.

What is being tested?

The HEROIC program is being tested to see if it can improve quality of life, reduce burden, and promote healthier lifestyles among caregivers of heart failure patients by focusing on their strengths and setting personal health goals.

What are the potential side effects?

Since this intervention involves a supportive program rather than medication, traditional side effects are not expected; however, participants may experience emotional responses as they engage in self-care practices.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 12 and 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 12 and 24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 12 and 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Caregiver Burden as assessed by the Oberst Caregiving Burden Scale

Change in Goal Attainment of Preventive Health Behaviors as measured by the Goal Attainment Scale

Change in Quality of Life as assessed by the Neurological Quality of Life(Neuro-QOL)

Secondary study objectives

Change in Self-Efficacy as assessed by the Coping Self Efficacy Scale

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Waitlist Control GroupExperimental Treatment1 Intervention

The waitlisted group will receive usual care for caregivers for the first 12 weeks, which is normally limited to inclusion in some clinical assessment and teaching during patient visits. Waitlisted participants will receive monthly study postcards to encourage retention. After 12 weeks, they will begin the intervention.

Group II: HEROIC Intervention GroupExperimental Treatment1 Intervention

This group will receive the HEROIC intervention.

Do I qualify?Apply below to find out